Abstract: The present disclosure relates, in some embodiments, to an apparatus for conducting a capillary electrophoresis assay. The apparatus can comprise a capillary array comprising an anode end and a cathode end, the capillary array provided in a housing further comprising a reservoir configured to house a separation medium and an anode buffer. The system can also comprise an injection mechanism configured to deliver sample to the cathode end of the capillary array, and a temperature control zone, wherein the temperature control zone is configured to control the temperature of the interior of the housing.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: Exemplary embodiments of rotary pulsers are provided that include a stator and a rotor rotationally disposed adjacent to the stator. The rotary pulsers can include a regulator mechanism and a pump. Based on a parameter or condition associated with the rotary pulser, the regulator mechanism can adjust a parameter of the pump to control rotation of the rotor. Exemplary embodiments are also directed to methods of regulating a rotary pulser.

Abstract: An alternator and starter tester system capable of generating a warranty claim code. The warranty claim code can contain information regarding a diagnostic test and the tested components. The alternator and starter tester system can also encode and transmit the warranty claim code to a supplier or a manufacturer to verify warranty credit.

Abstract: The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof. The methods of the invention comprises administering to the subject an effective amount of a HK2 depleting agent that decreases the level of expression and/or activity of HK2. In some embodiments, the level of expression and/or activity of fibroblast growth factor receptor (FGFR), FGF ligand and/or FGF signaling is/are decreased. The invention also includes methods for diagnosing excessive vascular development and for measuring the efficacy of a treatment for an excessive vascular development in a subject in need thereof. The invention further includes a pharmaceutical composition for treating or reducing angiogenesis or lymphangiogenesis, comprising a HK2 depleting agent and a pharmaceutical acceptable carrier.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: The present disclosure relates, in some embodiments, to an apparatus for conducting a capillary electrophoresis assay. The apparatus can comprise a capillary array comprising an anode end and a cathode end, the capillary array provided in a housing further comprising a reservoir configured to house a separation medium and an anode buffer. The system can also comprise an injection mechanism configured to deliver sample to the cathode end of the capillary array, and a temperature control zone, wherein the temperature control zone is configured to control the temperature of the interior of the housing.

Abstract: Method and apparatus for signal detection in dynamic channels with high carrier frequency offset are provided. A coherent detector and a non-coherent detector are operated in parallel on a block of samples of an input signal to determine respective time offset candidates of the input signal. The time offset candidate obtained from the non-coherent detector is used to determine a frequency offset candidate of the input signal.

Abstract: Exemplary embodiments of rotary pulsers are provided that include a stator and a rotor rotationally disposed adjacent to the stator. The rotary pulsers can include a regulator mechanism and a pump. Based on a parameter or condition associated with the rotary pulser, the regulator mechanism can adjust a parameter of the pump to control rotation of the rotor. Exemplary embodiments are also directed to methods of regulating a rotary pulser.

Abstract: An improved device and system for power transmission. A power transmission device comprises a primary winding magnetically coupled to a resonant secondary which comprises a plurality of magnetic resonators, each magnetic resonator comprising a magnetic winding. The magnetic resonators are connected in series and arranged so that the magnetic axis of each magnetic resonator is coupled to the primary winding. In operation, a power source supplies alternating current at an operating frequency to the primary of a power transmission device used as a transmitter. A load is coupled to the primary of a power transmission device used as a receiver. Collectors may be coupled to either or both of the transmit or receive device. A return line may be coupled to either or both of the transmit or receive device.

Abstract: A device and system for power transmission. A power transmission system comprises an RF power source coupled to one or more emitters producing a field which transfers power to one or more sinks. A sink comprises one or more collectors coupled to a resonator, which couples RF power from the collectors and resonator to harvesting electronics which convert the RF power to direct current to power a load. Emitters coupled to the source produce a field which is harvested by the sink and converted to DC for a load. Emitters and collectors may be capacitively coupled, or coupled through a conductive path. Coupling may include a ground path. Charge mobility elements may be used with emitters and/or collectors.

Abstract: An external service application discovery process that connects a host with an external application server running a service application allowing a user of a client computing device to work with a file via a web browser. The host brokers the functionality of an external application server and serves as the platform where interactions between the client computing device and the external application server occur. An open interface protocol, which is a shared communication protocol, allows the host to communicate instructions from the client computing device to the external application server. Through the external service application discovery process, the external application server describes functionality provided by the service application to the host.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

Abstract: A measuring device for measuring a signal with a first component signal and at least one second component signal comprises a high-frequency processing device, which is embodied to mix the signal in order to form an intermediate-frequency signal and to digitize the latter in order to form a digital composite signal. The measuring device further comprises a digital mixer, which is embodied to generate a first digital composite test signal and a second digital composite test signal subject to a displacement of the frequency of the digital composite signal. Moreover, the measuring device comprises a digital filter, which is embodied to filter the first digital composite test signal in order to form a first digital test signal and to filter the second digital composite test signal in order to form a second digital test signal.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.